1. Home
  2. ELF vs CRSP Comparison

ELF vs CRSP Comparison

Compare ELF & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo e.l.f. Beauty Inc.

ELF

e.l.f. Beauty Inc.

HOLD

Current Price

$77.35

Market Cap

4.9B

ML Signal

HOLD

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$57.08

Market Cap

5.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELF
CRSP
Founded
2004
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
5.6B
IPO Year
2016
2016

Fundamental Metrics

Financial Performance
Metric
ELF
CRSP
Price
$77.35
$57.08
Analyst Decision
Buy
Buy
Analyst Count
16
19
Target Price
$130.06
$71.50
AVG Volume (30 Days)
2.3M
2.4M
Earning Date
11-05-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.40
N/A
Revenue
$1,385,640,000.00
$38,337,000.00
Revenue This Year
$20.59
N/A
Revenue Next Year
$16.92
$723.84
P/E Ratio
$55.37
N/A
Revenue Growth
13.80
N/A
52 Week Low
$49.40
$30.04
52 Week High
$150.99
$78.48

Technical Indicators

Market Signals
Indicator
ELF
CRSP
Relative Strength Index (RSI) 38.97 52.31
Support Level $73.74 $51.16
Resistance Level $84.38 $59.77
Average True Range (ATR) 3.82 3.04
MACD 2.46 1.00
Stochastic Oscillator 60.55 77.28

Price Performance

Historical Comparison
ELF
CRSP

About ELF e.l.f. Beauty Inc.

e.l.f. Beauty Inc is a multi-brand beauty company that offers inclusive, accessible, clean, vegan, and cruelty-free cosmetics and skin care products. The Company's mission is to make beauty accessible to every eye, lip, face, and skin concern. The company offers cosmetic accessories for women, which include eyeliner, mascara, false eyelashes, lipstick, foundation for the face, moisturizer, cleanser, and other tools through its stores and e-commerce channels.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: